The Premium Business Information Source™
Report title:
THERAPEUTICS REVIEW: IMMUNE DISORDERS & INFLAMMATION
from
TF Market Research
23 page report published Jun 05, 2002
Price
$920.00
available for immediate download
This report is also available for purchase on a
per-page basis
.
Report Overview
Purchase by Section
About TF Market Research
Source:
DATAMONITOR
Geographic Region:
INTERNATIONAL
Industries:
BIOTECHNOLOGY, HEALTH CARE, PHARMACEUTICALS
Product:
ANTIARTHRITIC DRUGS
Subjects:
COMPANY ANALYSES, MARKET SIZE/DEMOGRAPHICS, FINANCIAL INFORMATION, INDUSTRY OVERVIEW/OUTLOOK, LINES OF BUSINESS/PRODUCTS, NEW PRODUCTS/SERVICES, PROJECTIONS, SALES/EARNINGS
Format:
PDF
Sections
Title
Starting Page
Number of Pages
CHAPTER 1 R&D UPDATE: ARTHRITIS
1
2
CHAPTER 1 R&D UPDATE: ARTHRITIS
1
2
CHAPTER 2 R&D UPDATE: OTHER IDI
2
2
CHAPTER 2 R&D UPDATE: OTHER IDI
3
2
CHAPTER 3 INDUSTRY COMMENT
3
1
CHAPTER 3 INDUSTRY COMMENT
5
1
Pharmacia: increasing its domination in pain
3
2
Pharmacia: increasing its domination in pain
5
2
CHAPTER 4 INDUSTRY ANALYSIS
4
1
CHAPTER 4 INDUSTRY ANALYSIS
7
1
Arthritis drugs: NSAIDs to grow 4.9% per year
4
1
Arthritis drugs: NSAIDs to grow 4.9% per year
7
1
Arthritis: total market worth $21 billion in 2008
4
1
Arthritis: total market worth $21 billion in 2008
8
1
CHAPTER 5 EXPERT ANALYSIS
4
1
CHAPTER 5 EXPERT ANALYSIS
9
1
Merck: the victim of definitions
4
3
Merck: the victim of definitions
9
3
CHAPTER 6 NEWS HEADLINES: ARTHRITIS
6
1
CHAPTER 6 NEWS HEADLINES: ARTHRITIS
12
1
Improvement reported in rheumatoid arthritis symptoms 48
6
1
Improvement reported in rheumatoid arthritis symptoms 48 hours after initial treatment with Remicad
12
1
Law firm investigates claims of deaths as a result of the
6
1
Law firm investigates claims of deaths as a result of the arthritis drug Arava
12
1
Abbott applies for US and European approval for rheumatoid
6
1
Abbott applies for US and European approval for rheumatoid arthritis treatment D2E7
12
1
Abbott enjoys 17.7% Q1 sales increase and looks to the
6
1
Abbott enjoys 17.7% Q1 sales increase and looks to the future with D2E7 applications and Red Cross
12
1
Xoma begins enrollment for Xanelim's phase II efficacy
6
1
Xoma begins enrollment for Xanelim's phase II efficacy trial
12
1
FDA approves Merck's changes to Vioxx labeling following
7
1
FDA approves Merck's changes to Vioxx labeling following study results
13
1
Genmab's HuMax-CD4 has long lasting effects in phase II
7
1
Genmab's HuMax-CD4 has long lasting effects in phase II trial
13
1
Merckle continues ML3000 development in US market
7
1
Merckle continues ML3000 development in US market
13
1
Merck's Arcoxia receives approval in the UK
7
1
Merck's Arcoxia receives approval in the UK
13
1
Immunex secures additional manufacturing capacity for
7
1
Immunex secures additional manufacturing capacity for Enbrel at Genentech
13
1
AtheroGenics completes phase I clinical trial for novel
7
1
AtheroGenics completes phase I clinical trial for novel intravenous rheumatoid arthritis treatment
13
1
KV receives another ANDA approval from the FDA
7
1
KV receives another ANDA approval from the FDA
14
1
Arthritis treatment may prove to be a suitable cancer drug
7
1
Arthritis treatment may prove to be a suitable cancer drug candidate
14
1
Protalex files for patent protection on its investigational
7
1
Protalex files for patent protection on its investigational rheumatoid arthritis treatment
14
1
Aventis and Vertex to expand development of pralnacasan
7
1
Aventis and Vertex to expand development of pralnacasan, oral cytokine inhibitor for inflammatory d
14
1
AnVil to undertake pilot project with Genomics
8
1
AnVil to undertake pilot project with Genomics collaborative to pursue rheumatoid arthritis treatme
14
1
Barr's generic Fosamax wins FDA tentative approval
8
1
Barr's generic Fosamax wins FDA tentative approval
14
1
Wyeth predicts Effexor sales will pass $2 billion in 2002
8
1
Wyeth predicts Effexor sales will pass $2 billion in 2002
15
1
Roche's R&D pipeline running smoothly
8
1
Roche's R&D pipeline running smoothly
15
1
ZymoGenetics' preclinical findings show Zfgf5 implicated in
8
1
ZymoGenetics' preclinical findings show Zfgf5 implicated in cartilage repair
15
1
CHAPTER 7 NEWS HEADLINES: OTHER IDI
8
1
CHAPTER 7 NEWS HEADLINES: OTHER IDI
16
1
Abbott Laboratories and Icagen expand drug discovery
8
1
Abbott Laboratories and Icagen expand drug discovery collaboration
16
1
Impax comments on Aventis lawsuit related to generic
8
1
Impax comments on Aventis lawsuit related to generic version of Allegra-D
16
1
ID Biomedical announces positive results from FluINsure
8
1
ID Biomedical announces positive results from FluINsure clinical trial
16
1
TNF-alpha blocker Infliximab highly effective for patients
8
1
TNF-alpha blocker Infliximab highly effective for patients with ankylosing spondylitis
16
1
Pharmaceutical Resources expands strategic product
8
1
Pharmaceutical Resources expands strategic product partnership with Merck KGaA
16
1
InterMune licenses oral drug to expand anti-fibrotic
9
1
InterMune licenses oral drug to expand anti-fibrotic franchise
17
1
Exelixis provides new insights into VEGF signaling A new
9
1
Exelixis provides new insights into VEGF signaling A new study by researchers at Exelixis and colla
17
1
RDP58 improves survival and decreases diarrhea related to
9
1
RDP58 improves survival and decreases diarrhea related to chemotherapy in animal studies
17
1
Enzon and Micromet forge collaboration for novel
9
1
Enzon and Micromet forge collaboration for novel single-chain antibody therapeutics
17
1
Structural GenomiX paid first milestone for determining
9
1
Structural GenomiX paid first milestone for determining structure of cystic fibrosis protein
17
1
Fougera set to become first to market generic version of
9
1
Fougera set to become first to market generic version of DesOwen
17
1
Genmab and Paradigm form human antibody discovery alliance
9
1
Genmab and Paradigm form human antibody discovery alliance
18
1
Genmab's HuMax-CD4 has long lasting effects in phase II
9
1
Genmab's HuMax-CD4 has long lasting effects in phase II trial
18
1
Canadian researchers find gene that regulates immune
9
1
Canadian researchers find gene that regulates immune response
18
1
AnorMED advances AMD-3100 for stem cell transplant
10
1
AnorMED advances AMD-3100 for stem cell transplant
18
1
BioMarin and Genzyme initiate "rolling" BLA filing for
10
1
BioMarin and Genzyme initiate "rolling" BLA filing for approval to market Aldurazyme in the US
18
1
GlaxoSmithKline and Unigene form osteoporosis alliance
10
1
GlaxoSmithKline and Unigene form osteoporosis alliance
18
1
Abgenix and Diabetogen to develop antibody therapy against
10
1
Abgenix and Diabetogen to develop antibody therapy against autoimmune disease
19
1
Orion and Quintiles form new drug development venture
10
1
Orion and Quintiles form new drug development venture
19
1
European patent strengthens Karo Bio project for treatment
10
1
European patent strengthens Karo Bio project for treatment of arteriosclerosis
19
1
EntreMed's Panzem safe and effective for treatment of
10
1
EntreMed's Panzem safe and effective for treatment of age-related macular degeneration
19
1
KV receives another ANDA approval from the FDA
10
1
KV receives another ANDA approval from the FDA
19
1
Cel-Sci discovers novel compound with very broad activity
10
1
Cel-Sci discovers novel compound with very broad activity
19
1
BMP-7 found to prevent bone disease in a model of chronic
11
1
BMP-7 found to prevent bone disease in a model of chronic kidney failure
19
2
Repligen receives approval for clinical trial of CTLA4-Ig
11
1
Repligen receives approval for clinical trial of CTLA4-Ig
20
1
Ligand to receive $3 million as Royalty Pharma exercises
11
1
Ligand to receive $3 million as Royalty Pharma exercises first option to purchase additional rights
20
1
Connetics' license partner files drug application for Olux
11
1
Connetics' license partner files drug application for Olux in the UK
20
1
Telik extends TRAP collaboration with Sanwa Kagaku
11
1
Telik extends TRAP collaboration with Sanwa Kagaku Kenkyusho
20
1
D Day for Claritin and Schering-Plough
11
1
D Day for Claritin and Schering-Plough
20
1
AstraZeneca and T Cell Sciences withdraw European
11
1
AstraZeneca and T Cell Sciences withdraw European opposition to Immune Response's T cell receptor p
21
1
HE2100 found to stimulate innate immunity in preclinical
11
1
HE2100 found to stimulate innate immunity in preclinical model of radiation injury
21
1
Altana and Pharmacia to collaborate in development and
11
1
Altana and Pharmacia to collaborate in development and commercialization of respiratory disease pro
21
1
Argenta Discovery to collaborate with Millennium
12
1
Argenta Discovery to collaborate with Millennium Pharmaceuticals on drug discovery program
21
1
New findings from a Princeton biologist could herald new
12
1
New findings from a Princeton biologist could herald new approach to lupus therapy
21
1
Schering welcomes committee's Claritin recommendations
12
1
Schering welcomes committee's Claritin recommendations
22
1
Xenova licenses novel immune inflammatory disease
12
1
Xenova licenses novel immune inflammatory disease treatments from Genentech
22
1
Xenova licenses novel immune inflammatory disease
12
1
Interleukin Genetics reaches milestone in inflammation gene research
22
1
Interleukin Genetics reaches milestone in inflammation gene
12
1
Johns Hopkins scientists on the brink of developing an autoimmune myocarditis vaccine from Cel-Sci
22
1
Johns Hopkins scientists on the brink of developing an
12
1
CollaGenex wins marketing approval for Periostat in Austria and Finland
22
1
CollaGenex wins marketing approval for Periostat in Austria
12
1
GlaxoSmithKline's controversial irritable bowel syndrome treatment wins FDA advisory panel's backin
22
1
GlaxoSmithKline's controversial irritable bowel syndrome
12
1
UCSD receives grant to advance rheumatic diseases knowledge base
23
1
UCSD receives grant to advance rheumatic diseases knowledge
13
1
Celltech and Biogen enter collaboration to develop and commercialize phase III Crohn's disease prod
23
1
Celltech and Biogen enter collaboration to develop and
13
1
Aventis and Vertex to expand development of pralnacasan, oral cytokine inhibitor for inflammatory d
23
1
Aventis and Vertex to expand development of pralnacasan
13
1
IDEC and Seikagaku extended their IDEC-152 alliance
23
1
IDEC and Seikagaku extended their IDEC-152 alliance
13
1
European marketing application for Thalomid accepted for review
23
1
European marketing application for Thalomid accepted for
13
1
ZLB Bioplasma launches its online University of Plasma
23
1
ZLB Bioplasma launches its online University of Plasma
13
1
TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.
Price: $920.00
Questions about
this research?
Send page to a friend
Return to
Alacra Company Snapshot
Get FREE Research
Sign up
here
to receive email alerts for FREE Research from Alacra Partners!
Can't Decide?
Purchasing premium research sight unseen can be intimidating. We want you to know what you are getting. Visit our
FAQ
or ask our
Customer Service Team
any questions about the report you are considering purchasing.
